Practical recommendations for the treatment of ascites and its complications
- PMID: 9339961
- DOI: 10.2165/00003495-199754040-00004
Practical recommendations for the treatment of ascites and its complications
Abstract
Ascites is one of the earliest and most common complications of patients with cirrhosis, and is associated with complications such as dilutional hyponatraemia, renal dysfunction and spontaneous bacterial peritonitis. The treatment of ascites has been based on the combination of a low-sodium diet and the administration of diuretics. The reintroduction of paracentesis and the recent introduction of the transjugular intrahepatic portosystemic shunt (TIPS) are the most relevant innovations in the treatment of ascites during the past 2 decades. The development of ascites is closely related to renal disturbances of functional origin, including the hepatorenal syndrome. A new definition of hepatorenal syndrome has been proposed recently and 2 different types have been defined (type I or progressive, and type III or stable). Although no effective therapy exists for this syndrome, the use of therapeutic methods (TIPS, vasoconstrictor agents, dialysis) to temporarily improve renal function and act as a 'bridge' to liver transplantation, may be of most benefit. The use of potent and safe antibiotics has improved the resolution rate and survival of patients with spontaneous bacterial peritonitis. In addition, the use of oral antibiotics will simplify the management of this condition in the near future. Finally, prophylactic antibiotic regimens represent a major step forwards in the prevention of spontaneous bacterial peritonitis in subsets of cirrhotic patients with a great risk of developing this complication.
Similar articles
-
Management of ascites and hepatorenal syndrome.Hepatol Int. 2018 Feb;12(Suppl 1):122-134. doi: 10.1007/s12072-017-9815-0. Epub 2017 Aug 23. Hepatol Int. 2018. PMID: 28836115 Review.
-
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.J Hepatol. 2010 Sep;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004. Epub 2010 Jun 1. J Hepatol. 2010. PMID: 20633946 Review. No abstract available.
-
Management of cirrhosis and ascites.N Engl J Med. 2004 Apr 15;350(16):1646-54. doi: 10.1056/NEJMra035021. N Engl J Med. 2004. PMID: 15084697 Review. No abstract available.
-
Management of cirrhotic ascites.Br J Hosp Med (Lond). 2015 Feb;76(2):C28-32. doi: 10.12968/hmed.2015.76.2.C28. Br J Hosp Med (Lond). 2015. PMID: 25671487 No abstract available.
-
Pathophysiology, complications, and treatment of ascites.Clin Liver Dis. 1997 May;1(1):129-55. doi: 10.1016/s1089-3261(05)70261-0. Clin Liver Dis. 1997. PMID: 15562674 Review.
Cited by
-
Effect of albumin-furosemide mixtures on response to furosemide in cirrhotic patients with ascites.Trans Am Clin Climatol Assoc. 2001;112:108-15; discussion 116. Trans Am Clin Climatol Assoc. 2001. PMID: 11413770 Free PMC article. Clinical Trial. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous